Somewhere in Scotland this morning, a woman helped her husband find his glasses for the third time before breakfast. She reminded him, gently, that it was Saturday. She made his tea exactly as he likes it — strong, a splash of milk — and for a moment everything felt normal.

For tens of thousands of Scottish families living with early-stage Alzheimer's disease, mornings like these are precious and precarious. The small forgettings that signal something larger. The quiet dread of what comes next.

But for the first time in decades, "what comes next" may not be inevitable decline. Two new drugs — lecanemab (sold as Leqembi) and donanemab (Kisunla) — have done something no Alzheimer's treatment has managed before: they don't just mask symptoms, they attack the disease itself.

A genuine breakthrough — with caveats

Both drugs are monoclonal antibodies that target amyloid, the rogue protein that builds up in the brains of Alzheimer's patients and is believed to drive the disease's devastating progression. In major clinical trials, lecanemab slowed cognitive decline by 27 per cent over 18 months, while donanemab slowed it by roughly a third.

To be clear: neither is a cure. Everyone in the trials still declined. But the treated patients declined meaningfully more slowly — holding on to independence, to recognition, to the thread of daily life, for longer.

Both drugs have been approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA). They exist. They work. And yet, as of today, neither is available on the NHS anywhere in the United Kingdom.

Scotland's frustrating wait

The Scottish Medicines Consortium (SMC) rejected lecanemab in February 2025 and donanemab in May 2025, concluding in both cases that the clinical benefit did not justify the cost. A further review of donanemab in February 2026 reached the same conclusion.

The decisions have been met with dismay by those closest to the disease.

"This demonstrates the urgent need for change in the system used to assess dementia drugs," said Henry Simmons, chief executive of Alzheimer Scotland, following the latest donanemab rejection. "We know that in countries where these treatments are available there is growing evidence that they are more effective in preventing disease progression than the clinical trial evidence suggests."

Alzheimer Scotland is now calling for a dedicated Dementia Drugs Fund — modelled on the Cancer Drugs Fund — to fast-track promising treatments into small-scale NHS pilot studies. "Dementia is the UK's biggest killer," Simmons said. "People living with this disease, their families and carers have been waiting decades for treatments that effectively slow its progression."

A door reopening

There is, however, a significant reason for hope. On 20 March 2026, the National Institute for Health and Care Excellence (NICE) announced it would reconsider both lecanemab and donanemab after their manufacturers successfully appealed. The companies argued that NICE had failed to properly account for the enormous burden on unpaid carers — estimated at over £20 billion a year across the UK.

"People living with dementia are desperate for new treatments that delay the progression of symptoms and help them stay independent for longer," said Michelle Dyson, chief executive of the Alzheimer's Society. "The science is moving fast and globally more people are starting to access these drugs, but the UK is falling behind."

If NICE reverses course, it could create momentum for the SMC to look again — and Scotland has been quietly building the infrastructure to be ready. Brain Health Scotland, working with the Scottish Government and NHS boards, launched the UK's first Brain Health Clinic in Aberdeen in 2023, in partnership with NHS Grampian. It has already supported more than 140 people and serves as a model for how early detection pathways could work across the country.

What comes next

The pipeline beyond lecanemab and donanemab is genuinely encouraging. More than 30 Alzheimer's disease drugs are currently in late-stage clinical trials worldwide. Researchers are exploring home-injectable versions of existing treatments — eliminating the need for hospital infusions — and next-generation therapies targeting different mechanisms entirely.

None of this erases the hard reality for families living with Alzheimer's today. The mornings will still be difficult. The glasses will still go missing.

But after decades in which the medical cupboard was bare, the shelves are finally filling. And Scotland — with the right political will, the right funding, and the right sense of urgency — could be among the first to open the door.